Exagen achieves key milestone with 1M patient tested by AVISE CTD

Exagen (XGN) announced the completion of its 1,000,000th AVISE CTD test, marking a significant milestone that underscores the company’s dedication to supporting patients and clinicians managing connective tissue diseases, CTD, and other autoimmune conditions. “Aiding in the care of our 1,000,000th patient is a huge milestone for our organization and demonstrates the value and utility that AVISE CTD provides in the care of patients with suspected autoimmune disease. We are very proud of reaching this level of adoption and look forward to continuing to support the rheumatologic community with future innovations,” said John Aballi, President and CEO of Exagen.